Deadline for receipt of abstracts: 01-02-2004
Name and address of corresponding author Name: Delanaye Pierre
Institute: CHU Sart Tilman Address: Service de Dialyse B35 Post code: 4000
City: LIEGE
Telephone: 043667111 fax: 043667205 e-mail: pierre_delanaye@yahoo.fr First author age < 35 years (born in 1969 or later): yes - no (please underline)
Abstract box
ABSTRACT FORM
Annual Scientific Meeting of the BVN/SBN, Liège, 1 April 2004
S
B V N
N
Instructions for authors:
1. Abstracts should be typed using single line spacing, Times 12 point font 2. Title: type in captials
3. Authors: Type in lower case. Underline the name of the presenting author. Write only the surname in full, and use initials for the first
name. At least one author must be a member of the SBN/BVN
4. Affiliation: type name of institute and city only. Use lower case 5. Body of the abstract: Organise the body of the abstract as follows:
a. State the purpose of the study b. Describe the methods
c. Summarize the results presented in sufficient details to support the conclusions d. Give the conclusions reached
6. Simple tables or graphs and maximum 3 references may be included if they fit within form rectangle
Abstracts should be sent by e-mail to: nadia.fenners@az.vub.ac.be before 01-02-2004 (receipt of your abstract will be acknowledged) For further information contact: Nadia Fenners, AZ-VUB, tel: 02/477 60 55, fax: 02/477 60 53, e-mail: nadia.fenners@az.vub.ac.be
TITLE: DETECTION OF RENAL FAILURE IN OVERWEIGHT PATIENTS
Authors: Delanaye P, Radermecker RP, Rorive M, Depas G, Chapelle JP, Gielen J, Krzesinski JM. Affiliation: CHU Sart Tilman, Liège.
Chronic renal failure is a frequent complication in obesity. Detection of renal failure is thus important in this population. The goal of this study is to compare serum creatinine with serum cystatin C in their ability to detect GFR under 60 ml/min/1.73 m2.
Patients with body mass index (BMI) over 27 kg/m2 were included. The reference method for GFR
measurement was Cr 51-EDTA (single injection method). GFR measured by Cr 51-EDTA was corrected by body surface area, calculated with the formula specifically developed for obese patients by Livingston. Serum creatinine was measured by compensated Jaffé method and cystatin C by particle-enhanced
nephelometric immunoassay method.
The population included 39 patients, 9 males and 30 women. Their mean age was 47.5 ± 11.5 years and their mean BMI was 39.3 ± 6.5 kg/m2. Seventeen patients had BMI over 40 kg/m2. The mean GFR
measured by Cr 51-EDTA was 78.4 ± 18 ml/min/1.73m2 (20 patients with GFR under 80 ml/min/1.73m2
and 7 patients with a GFR under 60 ml/min/1.73m2). Correlation between the reciprocal of creatinine and
GFR (r=0.31) is not significant (p=0.054) although correlation between the reciprocal of cystatin C and GFR (r=0.49) is statistically significant (p=0.0015). This difference between correlations is particularly high when the 17 patients with BMI over 40 kg/m2 are only considered (r=0.53 for cystatin versus r=-0.08
for creatinine). By ROC curves, sensitivity and specificity of both markers to detect GFR under 60 ml/min/1.73 m2 were analysed. For creatinine, area under the curve is not statistically different from ½
(AUC=0.65, p=0.24) although AUC for cystatin C is different from ½ (AUC=0.82, p=0.002).
Serum cystatin C appears thus better than serum creatinine to detect GFR under 60 ml/min/1.73 m2 in our
population of overweight patients. This new plasma marker seems particularly appropriate in case of severe obesity (BMI > 40 kg/m2). These preliminary results must yet be confirmed in a larger population.